AIM ImmunoTech (NYSEAMERICAN:AIM) Stock Price Down 2.7% – What’s Next?

Posted by Brian Himes on Sep 11th, 2026

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Get Free Report)’s share price fell 2.7% on Thursday . The company traded as low as $0.2150 and last traded at $0.2269. Approximately 10,380,839 shares changed hands during mid-day trading, a decline of 9% from the average session volume of 11,424,733 shares. The stock had previously closed at $0.2332.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reduced their price objective on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Get Our Latest Analysis on AIM ImmunoTech

AIM ImmunoTech Stock Performance

The company has a market capitalization of $6.91 million, a price-to-earnings ratio of -0.07 and a beta of 1.19. The business’s 50-day simple moving average is $0.25 and its 200-day simple moving average is $0.45.

AIM ImmunoTech (NYSEAMERICAN:AIM – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The firm had revenue of $0.03 million for the quarter. On average, analysts forecast that AIM ImmunoTech Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Corient Private Wealth LLC purchased a new stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned 1.31% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is owned by institutional investors and hedge funds.

About AIM ImmunoTech

(Get Free Report)

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.